The autoregressive integrated moving average with exogenous regressors (ARIMAX) modeling studies of pulmonary tuberculosis (PTB) are still rare. This study aims to explore whether incorporating air pollution and meteorological factors can improve the performance of a time series model in predicting PTB. We collected the monthly incidence of PTB, records of six air pollutants and six meteorological factors in Ningbo of China from January 2015 to December 2019. Then, we constructed the ARIMA, univariate ARIMAX, and multivariate ARIMAX models. The ARIMAX model incorporated ambient factors, while the ARIMA model did not. After prewhitening, the cross-correlation analysis showed that PTB incidence was related to air pollution and meteorological factors with a lag effect. Air pollution and meteorological factors also had a correlation. We found that the multivariate ARIMAX model incorporating both the ozone with 0-month lag and the atmospheric pressure with 11-month lag had the best performance for predicting the incidence of PTB in 2019, with the lowest fitted mean absolute percentage error (MAPE) of 2.9097% and test MAPE of 9.2643%. However, ARIMAX has limited improvement in prediction accuracy compared with the ARIMA model. Our study also suggests the role of protecting the environment and reducing pollutants in controlling PTB and other infectious diseases.
7 August 2025 in Frontiers in Cellular and Infection Microbiology
Rifampicin-resistant tuberculosis (RR-TB) remains a major global health challenge, with delayed sputum culture conversion (SCC) predicting poor treatment outcomes. This study integrated whole-genome sequencing (WGS) and machine learning to identify clinical and genomic determinants of SCC failure in 150 RR-TB patients (2019–2023). Phenotypic and genotypic analysis revealed high rates of isoniazid resistance (74.0%) and rpoB mutations (97.3%, predominantly Ser450Leu), with 90% of strains belonging to Lineage 2 (Beijing family). While 64.7% achieved 2-month SCC, 18.0% remained culture-positive at 6 months. Univariate analysis linked 2-month SCC failure to smear positivity, resistance to isoniazid, amikacin, capreomycin, and levofloxacin, and pre-XDR-TB status, though only smear positivity (aOR=2.41, P=0.008) and levofloxacin resistance (aOR=2.83, P=0.003) persisted as independent predictors in multivariable analysis. A Random Forest model achieved robust prediction of SCC failure (AUC: 0.86 ± 0.06 at 2 months; 0.76 ± 0.10 at 6 months), identifying levofloxacin resistance (feature importance: 6.37), embB_p.Met306Ile (5.94), and smear positivity (5.12) as top 2-month predictors, while katG_p.Ser315Thr (4.85) and gyrA_p.Asp94Gly (3.43) dominated 6-month predictions. These findings underscore smear positivity, levofloxacin resistance, and specific resistance mutations as critical drivers of SCC failure, guiding targeted RR-TB treatment strategies.
Background. The Mycobacterium tuberculosis H37Rv reference genome (Lineage 4), sequenced in 1998, may be incomplete and inaccurate due to earlier technology. Moreover, its use is problematic in regions like East Asia where the dominant Beijing lineage (Lineage 2) is prevalent, as it may introduce biases due to lineage-specific genetic differences. Methods. We performed hybrid sequencing to generate high-quality assemblies of a clinically isolated Beijing family strain (A2018772) and a Chinese laboratory-adapted H37Rv strain (H37Rv_CN). Comparative genomic analysis was conducted against the standard H37Rv reference. The impact of reference genome choice on transmission clustering was evaluated using a dataset of 3,359 M. tuberculosis Lineage 2 strains from China. Results. Comprehensive genomic analysis revealed substantial differences between both studied strains and H37Rv_ref. The Chinese laboratory-adapted H37Rv_CN strain differed by 145 SNPs, 49 InDels and 14 structural variants from the reference genome. The Beijing family clinical isolated strain A2018772 showed even greater divergence with 2,277 SNPs, 373 InDels and 219 structural variants compared to H37Rv_ref, with particular enrichment in PE/PPE genes and metabolic pathways. Among these variations, a 9.2 kb deletion was prevalent in 89.7% of 78 publicly available Lineage 2 genomes. When applied to transmission analysis of 3,359 Chinese Lineage 2 strains, the A2018772 as a reference genome demonstrated superior performance with higher mapping rates (99.52% vs. 98.72%) and coverage (99.73% vs. 98.50%) compared to H37Rv_ref. This improved resolution resulted in fewer transmission clusters (273 vs. 285) at the 5-SNP threshold, indicating that H37Rv_ref consistently overestimates transmission events in Lineage 2-dominated populations. Conclusion. Our study demonstrates the incompleteness of the H37Rv reference genome and also finds that using a lineage-specific reference genome could significantly improve transmission inference accuracy for Lineage 2 strains, highlighting the need for region-specific genomic references to enhance tuberculosis control strategies in high-burden areas.
22 October 2026 in Frontiers in Cellular and Infection Microbiology
Introduction: Routine whole-genome sequencing (WGS) interpretation of Mycobacterium tuberculosis resistance focuses mainly on consensus-level mutations. Minority variants, quantified by allele frequency (AF), may indicate resistant subpopulations under drug pressure, but their association with treatment response in rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB) remains unclear. Methods: We retrospectively analysed RR/MDR-TB patients treated in Ningbo, China, from 2021 to 2025, integrating clinical, phenotypic, treatment, microbiological, and WGS data. Minority resistance-associated variants (RAVs) were defined as low-frequency variants matching WHO V2 mutation catalogue entries at AF ≥ 3%, with AF ≥ 5% defining the primary higher-frequency subset. Per-drug analyses excluded patients whose target genes had median depth <200×. Associations with microbiological response were assessed using covariate-adjusted logistic regression, with higher-frequency and treatment-matched variants examined secondarily. Results: We analysed 229 RR/MDR-TB patients with linked WGS, treatment, and microbiological follow-up data. Fixed RAVs (WHO V2 catalogue-annotated) were carried by 220/229 patients (median 3, IQR 2–5). Minority RAVs at AF ≥ 3% were detected in 13 patients. Overall minority-RAV burden was not clearly associated with microbiological response after adjustment. The clearest signal involved treatment-matched AF ≥ 5% minority RAVs, whose carriers had a higher 6-month culture-positivity rate than non-carriers (4/7 [57.1%] vs 40/198 [20.2%]; adjusted odds ratio [aOR] 7.21, 95% CI 1.38–43.68; p = 0.020; q = 0.034), with a modest AUC increase from 0.675 to 0.695. Six-month positivity was highest among patients with both high fixed RAV burden and treatment-matched AF ≥ 5% minority RAVs (4/5 [80.0%] vs 15/106 [14.2%] in the low-burden non-carrier reference; Fisher’s exact p = 0.003). Conclusion: Minority variants showed limited overall prognostic value, but higher-frequency treatment-matched variants provided a coherent signal for 6-month culture positivity when considered with fixed RAV burden. These exploratory findings support a cautious, treatment-aware review of selected minority variants and require external validation before clinical use.
Background: The urinary lipoarabinomannan (LAM) assay has emerged as a promising tool for tuberculosis (TB) diagnosis and treatment monitoring. This study aimed to evaluate the diagnostic and monitoring performance of LAM compared to Acid-fast bacilli (AFB), Mycobacteria Growth Indicator Tube (MGIT), and GeneXpert, and to establish its clinical utility in a stratified TB population.Methods: A prospective cohort study included TB patients stratified by AFB/MGIT status into three groups. Diagnostic accuracy was tested against composite reference standard (CRS). Early monitoring performance was assessed via serial LAM measurements during 12-week treatment. ROC/KM/Cox analyses determined optimal thresholds and predictors of LAM conversion.Results: Against CRS, LAM demonstrated a sensitivity of 58.75%, which was numerically higher than AFB smear (45.00%, p = 0.082) and comparable to MGIT culture (58.75%, p = 1.00), but numerically lower than GeneXpert (61.25%, p = 0.205). In the early monitoring phase, LAM showed sustained positivity in 11.54–51.72% at week 12, compared to <15% for other methods. The diagnostic-monitoring quadrant analysis revealed LAM’s optimal positioning for monitoring (mean conversion time 4.63–11.49 weeks), compared to 0–8.25 weeks for other methods. A combined model incorporating baseline PreLAM and week 4 change (ΔLAM) showed the highest predictive value for 12 weeks conversion (AUC = 0.871–0.943). Multivariate cox analysis identified ΔLAM as independent predictors in total cohort (HR = 0.013, p = 0.001) and double positive group (HR = 0.020, p = 0.002).Conclusion: Urinary LAM serves as a dual-role biomarker, providing moderate diagnostic sensitivity and dynamic monitoring signals reflecting early bacillary response to therapy. The PreLAM+ΔLAM model enables early treatment response assessment for personalized therapy.
Objectives: Multi-drug-resistant tuberculosis (MDR-TB) continues to be a public health threat. Patients with MDR-TB commonly have a higher recurrence rate of hospital visits. However, previous studies have mainly focused on the time to the first event, while ignoring subsequent events. The objective of this study is to estimate the risk factors for the incidence of rehospitalization in MDR-TB patients.Methods: A retrospective longitudinal study was conducted on the MDR-TB patients who were consecutively enrolled from January 2015 to December 2021 in Ningbo, China. We fitted a multivariable Cox proportional hazard for time to first-event analysis, and extension of standard Cox model to consider multiple events.Results: The study included 337 patients, with a total of 1,255 hospitalization records analyzed and a median follow-up period of 46 months. Younger age (HR = 0.34, 95% CI: 0.20–0.57) and residing in urban areas (HR = 0.55, 95% CI: 0.37–0.83) were identified as protective factors against hospital readmission of MDR-TB patients. In contrast, outdoor service workers (HR = 1.51, 95% CI: 1.01–2.26) and migrants (HR = 1.79, 95% CI: 1.07–2.98) were associated with an increased risk of against hospital readmissions of MDR-TB patients. Furthermore, the extended Cox model revealed that both migrant status and the use of Group B medications significantly elevated the risk of hospital readmission of MDR-TB patients.Conclusion: MDR-TB remains a heavy public health issue, especially those with the independent risk factors of living in the rural areas and migrants. Social health protection schemes and government financing are essential for ensuring early diagnosis and appropriate treatment of MDR-TB.